Research programme: enzyme inhibitors - ZensunAlternative Names: ZS03
Latest Information Update: 20 Jul 2016
At a glance
- Originator Zensun (Shanghai) Sci & Tech
- Class Cardiovascular therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiomyopathies; Neurological disorders
Most Recent Events
- 20 Jul 2016 Preclinical trials in Neurological disorders in China (unspecified route) (Zensun pipeline, July 2016)
- 20 Jul 2016 Preclinical trials in Cardiomyopathy in China (unspecified route) (Zensun pipeline, July 2016)